Treatment Clinical Trials for Pancreatic Cancer

Clinical trials are research studies that involve people. The clinical trials on this list are for pancreatic cancer treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 51-75 of 212
< Previous 1 2 3 4 5 ... 9 Next >

  • Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients with Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

    This phase I / II trial studies the side effects and best dose of liposomal irinotecan and rucaparib and when given together with fluorouracil and leucovorin calcium and to see how well they work in treating patients with pancreatic, colorectal, gastroesophageal, or biliary cancer that has spread to other places in the body. Drugs used in chemotherapy, such as liposomal irinotecan, fluorouracil, leucovorin calcium, and rucaparib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
    Location: 4 locations

  • A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

    This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or in combination with CDX-301, and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
    Location: 4 locations

  • FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors

    This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: - Regimen A: FATE-NK100 as a monotherapy in subjects with advanced solid tumor malignancies. - Regimen B: FATE-NK100 in combination with trastuzumab in subjects with human epidermal growth factor receptor 2 positive (HER2+) advanced breast cancer, HER2+ advanced gastric cancer or other advanced HER2+ solid tumors. - Regimen C: FATE-NK100 in combination with cetuximab in subjects with advanced colorectal cancer (CRC) or head and neck squamous cell cancer (HNSCC), or other epidermal growth factor receptor 1 positive (EGFR1+) advanced solid tumors.
    Location: 3 locations

  • Gemcitabine Hydrochloride, Nab-Paclitaxel, and Ficlatuzumab in Treating Patients with Advanced Pancreatic Cancer

    This phase Ib trial studies the side effects and best dose of ficlatuzumab when given together with gemcitabine hydrochloride and nab-paclitaxel in treating patients with pancreatic cancer that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as ficlatuzumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as gemcitabine hydrochloride and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ficlatuzumab, gemcitabine hydrochloride, and nab-paclitaxel may work better in treating patients with pancreatic cancer.
    Location: 3 locations

  • Pembrolizumab and Hsp90 inhibitor XL888 in Treating Patients with Advanced Gastrointestinal Cancer

    This phase Ib trial studies the side effects and best dose of Hsp90 inhibitor XL888 when given together with pembrolizumab in treating patients with advanced gastrointestinal cancer that has spread to other places in the body. Hsp90 inhibitor XL888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving Hsp90 inhibitor XL888 with pembrolizumab may work better in treating patients with gastrointestinal cancer.
    Location: 3 locations

  • A Phase 1 / 2 Safety Study of Intratumorally Dosed INT230-6

    This study evaluates the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study is being conducted in patients with several types of refractory cancers including those at the surface of the skin (melanoma, head and neck, lymphoma, breast) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also plans to test INT230-6 in combination with anti-PD-1 antibodies.
    Location: 3 locations

  • Anetumab Ravtansine in Treating Patients with Mesothelin Positive, Locally Advanced, or Metastatic Pancreatic Cancer That Cannot Be Removed by Surgery

    This phase II trial studies how well anetumab ravtansine works in treating patients with mesothelin positive pancreatic cancer that has spread to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as anetumab ravtansine, may find tumor cells and help kill them.
    Location: 3 locations

  • A Phase 1 / 2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies

    This is a two-part Phase 1 / 2 dose escalation and dose expansion study of the GMCSF-encoding adenovirus, ONCOS-102, in combination with anti-programmed death ligand-1 (PDL1) antibody, durvalumab, in adult subjects with peritoneal disease who have failed prior standard chemotherapy and have histologically confirmed platinum-resistant or refractory epithelial ovarian cancer or colorectal cancer.
    Location: 3 locations

  • A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer

    This study is to define the safety profile and to determine the Maximal tolerated dose regimen and preliminary efficacy of AbGn-107 administered every 14 days (Q2W regimen) or 28 days (Q4W regimen) in patients with chemo-refractory locally advanced, recurrent or metastatic gastric, colorectal, pancreatic or biliary cancer.
    Location: 3 locations

  • A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced / Metastatic Cancer

    The purpose of this study is to determine the safety of an extracellular signal regulated kinase (ERK1 / 2) inhibitor LY3214996 administered alone or in combination with other agents in participants with advanced cancer.
    Location: 7 locations

  • Study Assessing Safety and Efficacy of Combination of BL-8040 and Pembrolizumab in Metastatic Pancreatic Cancer Patients (COMBAT / KEYNOTE-202)

    This study will assess the efficacy and safety of BL-8040 in combination with pembrolizumab (Keytruda®) and BL8040 / Pembrolizumab in combination with liposomal irinotecan (Onivyde®) / 5-fluorouracil / leucovorin (5-FU / LV) in subjects with metastatic pancreatic adenocarcinoma.
    Location: 4 locations

  • Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

    Phase Ib dose escalation in advanced solid tumors to identify dose for Phase II dose expansion in advanced or metastatic pancreatic cancer and KRAS-mutant colorectal cancer. Open-label, nonrandomized.
    Location: 4 locations

  • Capecitabine and Radiation Therapy with or without Pembrolizumab in Treating Participants with Resectable or Borderline Resectable Pancreatic Cancer

    The phase Ib / II trial studies the side effects of capecitabine and radiation therapy with or without pembrolizumab in treating participants with pancreatic cancer that can be removed by surgery. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. It is not known if giving capecitabine and radiation therapy with or without pembrolizumab will work better in treating participants with pancreatic cancer.
    Location: 3 locations

  • A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

    In this Phase II study a dose of 2.8 mg (eight 0.35 mg siG12D-LODERs) will be administered in 12-week cycles to patients with unresectable locally advanced pancreatic cancer combined with chemotherapy treatment. Primary Outcome: - Progression-free survival (PFS) in the study population.
    Location: 3 locations

  • Stereotactic Radiosurgery in Treating Patients with Oligo-Recurrent Disease

    This phase II trial studies how well stereotactic radiosurgery works in treating patients with cancer that has come back and has spread to 5 or fewer places in the body (oligometastatic disease). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.
    Location: 3 locations

  • Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease

    This phase II trial studies how well stereotactic radiosurgery works in treating patients with cancer that has spread to 5 or fewer places in the body and involves 3 or fewer organs (oligometastatic disease). Stereotactic radiosurgery, also known as stereotactic body radiation therapy, is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may kill more tumor cells and cause less damage to normal tissue.
    Location: 3 locations

  • FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

    FT500 is an off-the-shelf, iPSC-derived NK cell product that can bridge innate and adaptive immunity, and has the potential to overcome multiple mechanisms of immune checkpoint inhibitor (ICI) resistance. The preclinical data provide compelling evidence supporting the clinical investigation of FT500 as monotherapy and in combination with ICI in subjects with advanced solid tumors.
    Location: 3 locations

  • Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

    This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.
    Location: 2 locations

  • A Study of RGX-202-01 With or Without FOLFIRI in Patients With Advanced Gastrointestinal Malignancies

    RGX-202-001 is a Phase 1, first-in-human, dose escalation and expansion study of RGX-202-01 as a single agent and in combination with FOLFIRI. RGX-202-01 is a small molecule inhibitor of the creatine transporter SLC6a8, a novel metabolic target that drives gastrointestinal cancer progression. During the dose escalation stage, multiple doses of orally administered RGX-202-01 with or without FOLFIRI (single agent or combination therapy) will be evaluated in patients with advanced gastrointestinal tumors (i.e., locally advanced and unresectable, or metastatic) who have had PD on available standard systemic therapies or for which there are no standard systemic therapies of relevant clinical impact. In the expansion stage of the study, additional patients with advanced gastrointestinal malignancies selected by expression of the creatine kinase B (CKB) biomarker, gastric / gastroesophageal cancer, or colorectal cancer (CRC) will be treated at the MTD (or maximum tested dose if no MTD is identified, or dose below the MTD if there is evidence suggesting a more favorable risk / benefit profile). This stage will provide further characterization of the safety, efficacy, PK, and pharmacodynamics of RGX-202-01 as a single agent (selected by expression of the CKB biomarker) and in combination with FOLFIRI (gastric / gastroesophageal cancer and CRC).
    Location: 3 locations

  • A Phase I / Ib Study of NZV930 Alone and in Combination With PDR001 and / or NIR178 in Patients With Advanced Malignancies.

    The purpose of this study is to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and / or NIR178, in patients with advanced cancers
    Location: 2 locations

  • PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

    The purpose of this first-in-human study of CX-2029 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-2029 in adult subjects with metastatic or locally advanced unresectable solid tumors or diffuse large B-cell lymphoma (DLBCL). PROCLAIM: PRObody CLinical Assessment In Man CX-2029 clinical trial 001 PROBODY is a trademark of CytomX Therapeutics, Inc
    Location: 3 locations

  • Paricalcitol, Gemcitabine Hydrochloride, and Nab-Paclitaxel in Treating Patients with Metastatic Pancreatic Cancer

    This phase I / II trial studies the side effects and how well paricalcitol, gemcitabine hydrochloride, and nab-paclitaxel work in treating patients with pancreatic cancer that has spread to other places in the body. Paricalcitol is a form of vitamin D that works by blocking a signal in the cancer tumor cells that leads to growth and spreading of the tumor. Drugs used in chemotherapy, such as gemcitabine hydrochloride and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving paricalcitol, gemcitabine hydrochloride, and nab-paclitaxel may work better in treating patients with metastatic pancreatic cancer.
    Location: 2 locations

  • Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in Combination With GC4419 in Pancreatic Cancer

    The purpose of the phase I / II clinical study is to determine the best dose of fractionated stereotactic radiation therapy (SBRT) given either with GC4419 or placebo to patients who have been diagnosed with locally advanced pancreatic cancer.
    Location: 2 locations

  • A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

    The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic pancreatic cancer, colorectal cancer (CRC), squamous esophageal cancer (sqEC), and squamous non-small-cell lung cancer (sqNSCLC).
    Location: 2 locations

  • Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC

    The study is a multi-center, un-blinded, randomized control study of subjects with locally advanced pancreatic adenocarcinoma which is unresectable.
    Location: 3 locations


< Previous 1 2 3 4 5 ... 9 Next >